← Back to Search

Behavioral Intervention

Digital CBT for Insomnia in Healthcare Workers (HCW-CBTi Trial)

N/A
Recruiting
Led By Mandeep Singh, MD, FRCPC
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial will study if digital CBTi can help frontline healthcare workers (HCWs) caring for COVID-19 patients get better sleep, mental health, wellness, and quality of life.

Who is the study for?
This trial is for frontline healthcare workers experiencing insomnia, with a score of 16 or lower on the Sleep Condition Indicator. They must be actively involved in patient care during the COVID-19 pandemic and have access to a mobile phone or computer with internet. Those with urgent CBT needs, recent CBT treatment, additional sleep disorders like apnea or restless legs syndrome, severe medical/psychiatric conditions, or participating in other treatments/drug trials are excluded.
What is being tested?
The study tests if digital Cognitive Behavioral Therapy for Insomnia (dCBTi) can improve sleep health, mental well-being, and quality of life among healthcare workers caring for COVID-19 patients. It's a Canada-wide randomized controlled trial comparing dCBTi's effectiveness against usual care practices.
What are the potential side effects?
Since dCBTi is a non-pharmaceutical therapy involving behavioral changes and education through digital means, it typically does not have direct physical side effects like medication might. However, participants may experience frustration or stress if they find adapting new sleeping habits challenging.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Assessing changes in the nature and severity of insomnia
Secondary study objectives
Acceptability E-scale
Generalized Anxiety Disorder (GAD) 7
Impact of Event Scale
+10 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: Attention Control armActive Control1 Intervention
Participants in the control group will have access to online the sleep diary and sleep education material for 12 weeks, without the CBTi intervention by the Sleepio™ app (Big Health Ltd., London, UK). They will start the digital cognitive behavioral therapy for insomnia (dCBTi) intervention 12 weeks after the initial enrollment.
Group II: Intervention armActive Control1 Intervention
Digital CBTi will be offered using the SleepioTM website and supporting Sleepio™ app (Big Health Ltd., London, UK) via 6 sessions training program (spanning 6 to 12 weeks), lasting an average of 20 minutes each, unlocked weekly. The participant will receive the Sleepio intervention as soon as they become assigned.

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,521 Previous Clinical Trials
502,938 Total Patients Enrolled
Mandeep Singh, MD, FRCPCPrincipal InvestigatorAssociate Professor, Department of Anesthesiology and Pain Medicine, Toronto Western Hospital, UHN
1 Previous Clinical Trials
50 Total Patients Enrolled

Media Library

Digital Cognitive Behavioral Therapy for Insomnia (dCBTi) (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05816304 — N/A
Generalized Anxiety Disorder Research Study Groups: Attention Control arm, Intervention arm
Generalized Anxiety Disorder Clinical Trial 2023: Digital Cognitive Behavioral Therapy for Insomnia (dCBTi) Highlights & Side Effects. Trial Name: NCT05816304 — N/A
Digital Cognitive Behavioral Therapy for Insomnia (dCBTi) (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05816304 — N/A
~20 spots leftby Dec 2024